Welcome to our dedicated page for Biomea Fusion SEC filings (Ticker: BMEA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biomea Fusion, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD corporate presentations, clinical-program updates, and capital-structure information for its common stock.
The company’s proxy materials cover annual meeting voting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. These filings frame Biomea’s disclosures around icovamenib, BMF-650, pipeline development, financing needs, governance, and public-company reporting obligations.
Biomea Fusion, Inc. reported a net loss of $12.4 million for the quarter ended March 31, 2026, narrower than the $29.3 million loss a year earlier, as it sharply reduced research and development and administrative spending while remaining pre‑revenue.
Quarter-end cash, cash equivalents and restricted cash totaled $45.1 million, with management stating this is expected to fund operations only into the first quarter of 2027, creating substantial doubt about the company’s ability to continue as a going concern without additional financing. The company focuses on clinical-stage diabetes and obesity programs, including Phase II trials of icovamenib in type 2 diabetes and a Phase I trial of BMF-650 in obesity, and ended the quarter with 72.3 million common shares outstanding and a $461.5 million accumulated deficit.
Biomea Fusion reported first quarter 2026 results and clinical progress in its diabetes and obesity programs. The company is advancing icovamenib, a potential first-in-class oral menin inhibitor for type 1 and type 2 diabetes, and BMF-650, an oral GLP-1 RA candidate for obesity.
Chronic toxicology studies for icovamenib in two species were successfully completed, supporting chronic clinical dosing. In the Phase II COVALENT-112 trial in type 1 diabetes, patients on 200 mg icovamenib showed a 52% increase from baseline in mean C-peptide AUC at Week 12 and mean C-peptide AUC was largely preserved through Week 52 with about a 7% decline. Two Phase II T2D trials (COVALENT-211 and -212) and the Phase I GLP-131 obesity study are ongoing, with 26-week T2D topline data expected in the fourth quarter of 2026 and initial 28-day obesity data in the second quarter of 2026.
Financially, Biomea ended March 31, 2026 with $45.1 million in cash, cash equivalents and restricted cash and projects cash runway into the first quarter of 2027. Net loss narrowed to $12.4 million from $29.3 million a year earlier as R&D expenses fell to $9.1 million from $22.9 million and G&A expenses declined to $3.7 million from $6.8 million, reflecting lower external costs and headcount.
Biomea Fusion, Inc. reported topline 52‑week results from its Phase 2 COVALENT‑112 trial of icovamenib in adults with type 1 diabetes. In patients diagnosed within 0–3 years and treated with 200 mg once daily for 12 weeks, mean C‑peptide area under the curve increased by 52% at Week 12 (p<0.001; n=5), indicating a statistically robust rise in endogenous insulin secretion.
After stopping treatment, mean C‑peptide AUC in this cohort showed only about a 7% decline from baseline by Week 52, suggesting durability of effect. Patients with 3–15 years’ disease duration generally preserved C‑peptide through Week 52. Icovamenib was generally well tolerated over the 52‑week observation period, with no new or unexpected safety signals. The company plans a new Phase 2 trial in patients diagnosed within 3 years, testing extended 200 mg dosing for up to 6 or 12 months and exploring combination with an immunosuppressive JAK inhibitor at four U.S. diabetes centers.
Biomea Fusion, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 10, 2026. Holders of its 72,299,440 outstanding common shares as of April 13, 2026 may participate online and vote.
Stockholders are being asked to elect two Class II directors, co‑founder and President/COO Rainer (Ramses) Erdtmann and Lead Independent Director Eric Aguiar, M.D., to serve until the 2029 meeting, and to ratify Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. Deloitte billed audit fees of $1,160,774 in 2025 and $1,121,813 in 2024.
The proxy details board and committee structure, director independence, and compensation. Non‑employee directors receive cash retainers plus stock option grants sized to Black‑Scholes values of $360,000 at initial appointment and $185,000 annually. In 2025, Interim CEO Michael J.M. Hitchcock, Ph.D., earned salary of $486,739, a bonus of $220,076 and option awards valued at $1,848,576, while President/COO Erdtmann received salary of $489,604, a $146,881 bonus and option awards valued at $1,574,199. The company remains an “emerging growth company,” using scaled disclosure and reduced advisory vote requirements.
Biomea Fusion, Inc. director and officer Rainer M. Erdtmann received a grant of stock options covering 452,512 shares of common stock. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the award will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, subject to his continued service with the company. Following this grant, he holds 452,512 derivative securities directly.
Biomea Fusion, Inc. reported that Interim CEO and director Michael J.M. Hitchcock received a grant of stock options covering 667,477 shares of Common Stock on April 1, 2026. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the option will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, as long as Hitchcock continues to serve the company through each vesting date. Following this grant, he holds 667,477 derivative securities directly.
Biomea Fusion, Inc. files its annual report describing progress as a clinical-stage company developing oral small-molecule drugs for diabetes, obesity and metabolic disease. Following a 2025 strategic realignment, it now focuses on two core programs: icovamenib and BMF-650.
Lead candidate icovamenib, an oral covalent menin inhibitor, showed durable glycemic benefits in the Phase II COVALENT-111 trial, including a sustained placebo-adjusted HbA1c reduction of 1.5% at week 52 in severe insulin-deficient type 2 diabetes after only 12 weeks of dosing, and 1.8% in a post-hoc GLP-1 RA subgroup. More than 400 subjects have received icovamenib with a generally well-tolerated safety profile and no treatment-related serious adverse events reported.
Two new Phase II trials, COVALENT-211 and COVALENT-212, are enrolling type 2 diabetes patients not at glycemic targets, with a 26‑week primary endpoint readout expected in the fourth quarter of 2026. The company is also running Phase I trial GLP-131 for oral GLP‑1 RA candidate BMF‑650 in obesity, with initial 28‑day weight‑loss data expected in the second quarter of 2026.
Biomea Fusion reported full-year 2025 results and highlighted rapid progress in its diabetes and obesity pipeline. The company posted a net loss of $61.8 million, significantly narrower than $138.4 million in 2024, as research and development expenses fell to $62.0 million from $118.1 million following a strategic focus on core metabolic programs.
As of December 31, 2025, Biomea held $56.2 million in cash, cash equivalents and restricted cash and projects a cash runway into the first quarter of 2027. Clinically, lead menin inhibitor icovamenib showed durable 52‑week HbA1c reductions of about 1.2% in difficult‑to‑treat type 2 diabetes subgroups, with no treatment‑related serious adverse events or discontinuations.
The company initiated two Phase II icovamenib trials in type 2 diabetes with 26‑week endpoints and expects data in the fourth quarter of 2026, and completed 52‑week follow‑up in a Phase II type 1 diabetes study with data expected in the second quarter of 2026. Biomea also advanced oral GLP‑1 candidate BMF‑650 into the Phase I GLP‑131 obesity trial, with initial 28‑day weight‑reduction data anticipated in the second quarter of 2026.
Biomea Fusion filed an 8-K to share an updated corporate presentation outlining its pipeline for diabetes and obesity. The company highlights icovamenib, a potential first-in-class oral menin inhibitor designed to restore beta-cell function in type 2 diabetes, with two Phase II trials (COVALENT-211 and COVALENT-212) underway and 26-week primary endpoint data anticipated in 4Q 2026. Earlier Phase IIa data showed durable HbA1c reductions and increased C-peptide up to 52 weeks after a 12-week course, along with a generally favorable safety profile. Biomea also presents BMF-650, an investigational next-generation oral GLP-1 receptor agonist for obesity that achieved up to about 15% weight loss over 28 days in obese monkeys, with Phase I 28-day weight reduction data in obese volunteers expected in 2Q 2026. The company states it is funded through key readouts for icovamenib and BMF-650 into Q1 2027 and emphasizes large target populations across insulin-deficient diabetes, GLP-1 inadequate responders, and obesity.